- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 211/34 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Patent holdings for IPC class C07D 211/34
Total number of patents in this class: 448
10-year publication summary
|
31
|
21
|
27
|
33
|
29
|
32
|
37
|
22
|
27
|
6
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Incyte Corporation | 1060 |
15 |
| Zevra Therapeutics, Inc. | 109 |
13 |
| Incyte Holdings Corporation | 636 |
12 |
| Novartis AG | 10345 |
11 |
| Biogen MA Inc. | 931 |
11 |
| Nocion Therapeutics, Inc. | 50 |
10 |
| Boehringer Ingelheim International GmbH | 4510 |
8 |
| Praxis Precision Medicines, Inc. | 218 |
8 |
| ReNAgade Therapeutics Management Inc. | 56 |
8 |
| Massachusetts Institute of Technology | 10201 |
7 |
| The General Hospital Corporation | 4824 |
7 |
| Takeda Pharmaceutical Company Limited | 2721 |
7 |
| The Broad Institute, Inc. | 1932 |
7 |
| AstraZeneca AB | 2837 |
6 |
| Guangzhou Innocare Pharma Tech Co., Ltd. | 13 |
6 |
| ChemoCentryx, Inc. | 370 |
5 |
| H. Lee Moffitt Cancer Center and Research Institute, Inc. | 1010 |
5 |
| Telo Therapeutics, Inc. | 7 |
5 |
| The Regents of the University of Michigan | 4911 |
4 |
| Astellas Pharma Inc. | 1030 |
4 |
| Other owners | 289 |